Organon & Co., headquartered in Jersey City, develops innovative health solutions in women’s health, biosimilars, and established brands, employing 10,000 people and operating six manufacturing facilities worldwide. The company went public on May 14, 2021, and offers products like Nexplanon and Follistim AQ through various distribution channels.
OGN has been in the news recently: Organon & Company (NYSE: OGN) reported better-than-expected earnings for the third quarter, surpassing analysts' forecasts. This positive financial news comes as Wall Street shows signs of recovery, with investors expressing optimism about the potential resolution of the ongoing government shutdown.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.